Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

NCT06059261 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Envafolimab and recombinant human endostatin combined with chemoradiotherapy

Sponsor

Chongqing University Cancer Hospital